• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.

作者信息

Batlle J, Lopez-Fernandez M F, Lopez-Borrasca A, Lopez-Berges C, Dent J A, Berkowitz S D, Ruggeri Z M, Zimmerman T S

出版信息

Blood. 1987 Jul;70(1):173-6.

PMID:3496131
Abstract

The infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) in normal individuals is followed by an increase in factor VIII/von Willebrand factor (vWF) in plasma, by an increase in intensity of all sizes of multimers, and by the appearance of larger multimers of vWF than those seen in the resting state. Since the larger multimers are rapidly cleared and proteolysis is known to cause disaggregation of large multimers, we evaluated the degree of vWF proteolysis after DDAVP administration. DDAVP was infused into eight normal adult volunteers, and the relative proportions of the intact 225 kilodalton (kDa) subunit and the 189, 176, and 140 kDa vWF fragments were compared before and at different times after DDAVP infusion. The relative proportion of the 176 kDa fragment was increased, whereas that of the other species was decreased, thereby indicating that proteolytic fragmentation had occurred. However, plasmin did not appear to be responsible because the vWF fragments characteristically produced by this enzyme could not be detected. Concomitant analysis of vWF multimeric structure showed that these changes were accompanied by an increase in the relative proportion of the satellite bands, which suggests that they were proteolytically generated. Proteolysis may explain, at least in part, rapid clearance of larger vWF multimers released by DDAVP.

摘要

相似文献

1
Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.
Blood. 1987 Jul;70(1):173-6.
2
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.1型和2型先天性血管性血友病患者血管性血友病因子参数对去氨加压素的反应:诊断和治疗意义
Semin Thromb Hemost. 2002 Apr;28(2):111-32. doi: 10.1055/s-2002-27814.
3
Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.2A型和2B型血管性血友病变异体中血管性血友病因子寡聚体的不同组织形式:去氨加压素输注和蛋白酶抑制剂的作用
Ann Hematol. 1995 Oct;71(4):189-94. doi: 10.1007/BF01910317.
4
Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).
Am J Hematol. 1991 Mar;36(3):163-70. doi: 10.1002/ajh.2830360302.
5
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.血管性血友病的一种新变体(帕多瓦I型):在所有大小的多聚体存在下,由双重结构组成的血浆血管性血友病因子寡聚体
Haematologia (Budap). 1994;26(2):97-109.
6
Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.去氨加压素给药后因子VIII/血管性血友病因子的多聚体组成:对血管性血友病各亚型病理生理学和治疗的意义
Blood. 1982 Jun;59(6):1272-8.
7
Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.1型/2E型(2A亚型IIE)血管性血友病、1型维琴察型血管性血友病以及由血管性血友病因子基因的D3、D4、B1 - B3和C1 - C2结构域突变引起的轻型1型血管性血友病的实验室诊断。血管性血友病因子多聚体及血管性血友病因子前肽/抗原比值的作用。
Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8.
8
Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.去氨加压素对患有1型血管性血友病的杜宾犬血管性血友病因子多聚体的影响。
Am J Vet Res. 2005 May;66(5):861-7. doi: 10.2460/ajvr.2005.66.861.
9
Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.1型血管性血友病队列中去氨加压素释放后血管性血友病因子的存活:糖基化、蛋白水解和基因突变的影响
Thromb Haemost. 2008 May;99(5):916-24. doi: 10.1160/TH07-09-0565.
10
Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.重度血管性血友病患者对去氨加压素的释放作用不敏感:这证明去氨加压素诱导的血浆因子VIII增加并非继发于血浆血管性血友病因子的增加。
Br J Haematol. 1994 Feb;86(2):333-7. doi: 10.1111/j.1365-2141.1994.tb04735.x.

引用本文的文献

1
Mechanisms of ADAMTS13 regulation.ADAMTS13 的调控机制。
J Thromb Haemost. 2022 Dec;20(12):2722-2732. doi: 10.1111/jth.15873. Epub 2022 Sep 22.
2
von Willebrand factor, Jedi knight of the bloodstream.血管性血友病因子,血流中的绝地武士。
Blood. 2014 Aug 28;124(9):1412-25. doi: 10.1182/blood-2014-05-378638. Epub 2014 Jun 13.
3
Biology and physics of von Willebrand factor concatamers.von Willebrand 因子多聚体的生物学和物理学。
J Thromb Haemost. 2011 Jul;9 Suppl 1(0 1):130-43. doi: 10.1111/j.1538-7836.2011.04320.x.
4
Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.超大型血管蛋白血管性血友病因子的机械酶解作用
Science. 2009 Jun 5;324(5932):1330-4. doi: 10.1126/science.1170905.
5
Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.超大型血管蛋白血管性血友病因子中力感应结构域A2的结构特化
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9226-31. doi: 10.1073/pnas.0903679106. Epub 2009 May 21.
6
Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.常染色体显性遗传性C1149R型血管性血友病:表型特征及其意义。
Haematologica. 2009 May;94(5):679-86. doi: 10.3324/haematol.2008.003301. Epub 2009 Mar 13.
7
Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.在流体剪切应力作用下,血小板-血管性血友病因子复合物是ADAMTS13的首选底物。
Blood. 2008 Jan 15;111(2):651-7. doi: 10.1182/blood-2007-05-093021. Epub 2007 Sep 27.